One Pill or Three? Conflicting Research Puts HIV Generics in the Spotlight

On the face of things, the strategy makes perfect sense.

With the patent expiring on one of the three drugs in Atripla (the once-daily, single-pill antiretroviral used in first-line therapy in the U.S.), why not save money by using a cheap generic version of first drug (Sustiva), replacing the second (Emtriva) with a suitable generic (Epivir), and offering the branded drug component (Viread) on its own? Drug coverage providers in the U.S. could potentially save up to $1 billion per year, said an investigative team from Harvard Medical School this past July....Read Full Post

Source: About AIDS / HIV - May 15, 2013 Category: Consumer Health News Source Type: news